---
title: "CONBA: Perindopril and Amlodipine Tablets (Ⅲ) have obtained the drug registration certificate"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/250375632.md"
description: "According to the Zhitong Finance APP, CONBA announced that recently, its wholly-owned subsidiary Hangzhou CONBA Pharmaceutical Co., Ltd. (hereinafter referred to as \"Hangzhou CONBA\") received the drug registration certificate for Perindopril Amlodipine Tablets (III) issued by the National Medical Products Administration (hereinafter referred to as \"NMPA\")"
datetime: "2025-07-28T09:25:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/250375632.md)
  - [en](https://longbridge.com/en/news/250375632.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/250375632.md)
---

# CONBA: Perindopril and Amlodipine Tablets (Ⅲ) have obtained the drug registration certificate

According to the Zhitong Finance APP, CONBA (600572.SH) announced that its wholly-owned subsidiary Hangzhou CONBA Pharmaceutical Co., Ltd. (hereinafter referred to as "Hangzhou CONBA") has received the drug registration certificate for Perindopril Amlodipine Tablets (III) issued by the National Medical Products Administration (hereinafter referred to as "NMPA")

### Related Stocks

- [600572.CN](https://longbridge.com/en/quote/600572.CN.md)

## Related News & Research

- [11:05 ETThe Church of Jesus Christ of Latter-day Saints Commits $25 Million to the UNICEF-led Child Nutrition Fund](https://longbridge.com/en/news/287088476.md)
- [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)
- [Dunkin' To Give Away 1 Mln Free Coffees For A Day](https://longbridge.com/en/news/286964019.md)
- [20:38 ETHyundai Bioscience Discloses XAFTY®'s IC50 Data for Ebola--"Secured Scientific Evidence for Immediate Treatment"](https://longbridge.com/en/news/287135394.md)
- [BioInvent to Host Virtual KOL Event to Discuss BI-1808 for the Treatment of Ovarian Cancer, on May 27, 2026](https://longbridge.com/en/news/287043048.md)